|Articles|April 25, 2017

Schulman IRBs IBC Service to Launch in May

Schulman IRB announced its commercial institutional biosafety committee (IBC) service will launch in May 2017.

Schulman IRB announced its commercial institutional biosafety committee (IBC) service will launch in May 2017. The IBC service represents Schulman’s response to requests from research sponsors, CROs and institutions seeking an independent option for establishing IBCs when required by federal guidelines.

Read the full release here

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Schulman IRBs IBC Service to Launch in May

Related Content

Why Payment Performance Has Become an Operational Brand for Sponsors: Q&A with Patrick Mizer, Ledger Run

What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale

ACT Brief: Hidden RBQM Value, Rare Disease Patient Partnership, and Safety Perception in IBD

Beyond Patient Centricity: What Rare Disease Research Gets Right

The Unquantified Value of RBQM: Reduced Rework, Data Integrity, and Inspection Readiness

Trending on Applied Clinical Trials Online

Beyond Patient Centricity: What Rare Disease Research Gets Right

What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale

ACT Brief: Hidden RBQM Value, Rare Disease Patient Partnership, and Safety Perception in IBD

The Unquantified Value of RBQM: Reduced Rework, Data Integrity, and Inspection Readiness

Why Payment Performance Has Become an Operational Brand for Sponsors: Q&A with Patrick Mizer, Ledger Run